SOPHiA Genetics Posts 22% Q4 Revenue Growth, Guides $92–94M 2026 Revenue
SOPHiA Genetics processed nearly 1 petabyte of genomic data in 2025—double 2023 volumes—and completed 391,000 patient analyses using its next-gen DDM platform with under six-hour whole-genome runs. Q4 revenue climbed 22% year-over-year and 2026 guidance targets $92–94M in revenue with adjusted EBITDA breakeven by year-end.
1. Platform Scale and Performance
In 2025 SOPHiA processed nearly 1 petabyte of genomic data—double the volume from 2023—and analyzed 391,000 patient samples using its next-gen DDM platform, delivering whole-genome analyses in under six hours and supporting roughly 30,000 monthly samples across 75 countries.
2. Q4 Revenue and Commercial Momentum
In Q4 revenue rose 22% year-over-year to $21.7 million, with clinical revenue excluding biopharma up 31%. The company added 30 new customers in the quarter, saw average contract value rise 120% in 2025, and expanded adjusted gross margin to 73.9%.
3. 2026 Outlook and Leadership Transition
Management guides 2026 revenue of $92–94M (20–22% growth) with an adjusted EBITDA loss of $29–32M and breakeven expected by year-end. Ross Muken will become CEO on July 1 as co-founder Jurgi Camblong moves to Executive Chairman to focus on technology innovation.